BIO-TECHNE Corp (NASDAQ:TECH) has been assigned an average recommendation of “Buy” from the eleven ratings firms that are covering the company, Marketbeat Ratings reports. Four research analysts have rated the stock with a hold recommendation, six have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $189.13.

A number of research firms have recently issued reports on TECH. ValuEngine downgraded BIO-TECHNE from a “buy” rating to a “hold” rating in a research note on Tuesday, May 7th. BidaskClub upgraded BIO-TECHNE from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, April 10th. Zacks Investment Research upgraded BIO-TECHNE from a “hold” rating to a “strong-buy” rating and set a $238.00 price target on the stock in a research note on Wednesday, May 8th. Argus restated a “buy” rating on shares of BIO-TECHNE in a research note on Monday, March 4th. Finally, Craig Hallum restated a “hold” rating and issued a $179.00 price target (up from $154.00) on shares of BIO-TECHNE in a research note on Tuesday, February 5th.

TECH traded down $5.39 during trading on Friday, hitting $196.33. 1,219 shares of the company’s stock traded hands, compared to its average volume of 171,665. The company has a current ratio of 4.32, a quick ratio of 3.36 and a debt-to-equity ratio of 0.44. BIO-TECHNE has a 12-month low of $132.75 and a 12-month high of $207.84. The company has a market cap of $7.65 billion, a price-to-earnings ratio of 48.36, a P/E/G ratio of 4.31 and a beta of 1.24.

BIO-TECHNE (NASDAQ:TECH) last issued its earnings results on Tuesday, April 30th. The biotechnology company reported $1.21 EPS for the quarter, beating the consensus estimate of $0.94 by $0.27. BIO-TECHNE had a return on equity of 13.53% and a net margin of 17.15%. The business had revenue of $184.86 million for the quarter, compared to the consensus estimate of $183.92 million. During the same period last year, the business posted $1.21 EPS. The company’s revenue was up 12.7% compared to the same quarter last year. As a group, research analysts forecast that BIO-TECHNE will post 3.9 EPS for the current year.

The company also recently declared a quarterly dividend, which will be paid on Friday, May 24th. Stockholders of record on Friday, May 10th will be paid a $0.32 dividend. The ex-dividend date of this dividend is Thursday, May 9th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.65%. BIO-TECHNE’s dividend payout ratio (DPR) is currently 31.45%.

In other news, CFO James Hippel sold 35,000 shares of the firm’s stock in a transaction on Wednesday, May 1st. The stock was sold at an average price of $203.08, for a total value of $7,107,800.00. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 3.80% of the company’s stock.

Hedge funds have recently added to or reduced their stakes in the company. Commonwealth Equity Services LLC lifted its position in BIO-TECHNE by 1.6% during the fourth quarter. Commonwealth Equity Services LLC now owns 3,690 shares of the biotechnology company’s stock valued at $534,000 after purchasing an additional 58 shares in the last quarter. Creative Planning lifted its position in BIO-TECHNE by 4.1% during the first quarter. Creative Planning now owns 1,785 shares of the biotechnology company’s stock valued at $354,000 after purchasing an additional 71 shares in the last quarter. Flinton Capital Management LLC lifted its position in BIO-TECHNE by 2.5% during the fourth quarter. Flinton Capital Management LLC now owns 3,248 shares of the biotechnology company’s stock valued at $470,000 after purchasing an additional 80 shares in the last quarter. ETF Managers Group LLC lifted its position in BIO-TECHNE by 9.3% during the first quarter. ETF Managers Group LLC now owns 950 shares of the biotechnology company’s stock valued at $189,000 after purchasing an additional 81 shares in the last quarter. Finally, First Hawaiian Bank lifted its position in BIO-TECHNE by 59.9% during the first quarter. First Hawaiian Bank now owns 219 shares of the biotechnology company’s stock valued at $43,000 after purchasing an additional 82 shares in the last quarter. Hedge funds and other institutional investors own 93.92% of the company’s stock.

BIO-TECHNE Company Profile

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells biotechnology reagents, instruments, and clinical diagnostic controls worldwide. It operates in three segments: Biotechnology, Protein Platforms, and Diagnostics. The Biotechnology segment offers specialized proteins, such as cytokines and growth factors, immunoassays, antibodies, and related reagents to the biotechnology research community; and in situ hybridization, media, and other cell culture products and reagents.

Recommended Story: Why is Cost of Capital Important?

Analyst Recommendations for BIO-TECHNE (NASDAQ:TECH)

Receive News & Ratings for BIO-TECHNE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIO-TECHNE and related companies with MarketBeat.com's FREE daily email newsletter.